D
Aurinia Pharmaceuticals Inc.
AUPH
$7.20
-$0.39-5.14%
D
Sell
3/3/2025Upgraded
Aurinia Pharmaceuticals Inc. (AUPH) was upgraded to D+ from D- on 3/3/2025 due to a major increase in the efficiency index, total return index and volatility index.
Aurinia Pharmaceuticals Inc. (AUPH) was upgraded to D+ from D- on 3/3/2025 due to a major increase in the efficiency index, total return index and volatility index.
D
Sell
11/25/2024Upgraded
Aurinia Pharmaceuticals Inc. (AUPH) was upgraded to D- from E+ on 11/25/2024 due to an increase in the total return index, solvency index and volatility index.
Aurinia Pharmaceuticals Inc. (AUPH) was upgraded to D- from E+ on 11/25/2024 due to an increase in the total return index, solvency index and volatility index.
E
Sell
11/8/2024Downgrade
Aurinia Pharmaceuticals Inc. (AUPH) was downgraded to E+ from D- on 11/8/2024 due to a decline in the valuation index and growth index.
Aurinia Pharmaceuticals Inc. (AUPH) was downgraded to E+ from D- on 11/8/2024 due to a decline in the valuation index and growth index.
D
Sell
10/2/2024Upgraded
Aurinia Pharmaceuticals Inc. (AUPH) was upgraded to D- from E+ on 10/2/2024 due to a significant increase in the growth index, volatility index and total return index. Operating cash flow increased 185.19% from -$18.6M to $15.84M, earnings per share increased from -$0.0746 to $0.005, and EBIT increased 93.29% from -$6.57M to -$441.
Aurinia Pharmaceuticals Inc. (AUPH) was upgraded to D- from E+ on 10/2/2024 due to a significant increase in the growth index, volatility index and total return index. Operating cash flow increased 185.19% from -$18.6M to $15.84M, earnings per share increased from -$0.0746 to $0.005, and EBIT increased 93.29% from -$6.57M to -$441.
E
Sell
4/17/2024Downgrade
Aurinia Pharmaceuticals Inc. (AUPH) was downgraded to E+ from D- on 4/17/2024 due to a decline in the total return index and volatility index.
Aurinia Pharmaceuticals Inc. (AUPH) was downgraded to E+ from D- on 4/17/2024 due to a decline in the total return index and volatility index.
D
Sell
3/21/2024Upgraded
Aurinia Pharmaceuticals Inc. (AUPH) was upgraded to D- from E+ on 3/21/2024 due to an increase in the volatility index and valuation index.
Aurinia Pharmaceuticals Inc. (AUPH) was upgraded to D- from E+ on 3/21/2024 due to an increase in the volatility index and valuation index.
E
Sell
3/6/2024Downgrade
Aurinia Pharmaceuticals Inc. (AUPH) was downgraded to E+ from D- on 3/6/2024 due to a decline in the volatility index and total return index.
Aurinia Pharmaceuticals Inc. (AUPH) was downgraded to E+ from D- on 3/6/2024 due to a decline in the volatility index and total return index.
D
Sell
2/20/2024Upgraded
Aurinia Pharmaceuticals Inc. (AUPH) was upgraded to D- from E+ on 2/20/2024 due to an increase in the volatility index and valuation index.
Aurinia Pharmaceuticals Inc. (AUPH) was upgraded to D- from E+ on 2/20/2024 due to an increase in the volatility index and valuation index.
E
Sell
2/13/2024Downgrade
Aurinia Pharmaceuticals Inc. (AUPH) was downgraded to E+ from D- on 2/13/2024 due to a decline in the volatility index, growth index and total return index.
Aurinia Pharmaceuticals Inc. (AUPH) was downgraded to E+ from D- on 2/13/2024 due to a decline in the volatility index, growth index and total return index.
D
Sell
1/25/2024Upgraded
Aurinia Pharmaceuticals Inc. (AUPH) was upgraded to D- from E+ on 1/25/2024 due to an increase in the volatility index, total return index and valuation index.
Aurinia Pharmaceuticals Inc. (AUPH) was upgraded to D- from E+ on 1/25/2024 due to an increase in the volatility index, total return index and valuation index.
E
Sell
1/8/2024Downgrade
Aurinia Pharmaceuticals Inc. (AUPH) was downgraded to E+ from D- on 1/8/2024 due to a decline in the volatility index and total return index.
Aurinia Pharmaceuticals Inc. (AUPH) was downgraded to E+ from D- on 1/8/2024 due to a decline in the volatility index and total return index.
D
Sell
12/18/2023Upgraded
Aurinia Pharmaceuticals Inc. (AUPH) was upgraded to D- from E+ on 12/18/2023 due to an increase in the volatility index and solvency index.
Aurinia Pharmaceuticals Inc. (AUPH) was upgraded to D- from E+ on 12/18/2023 due to an increase in the volatility index and solvency index.
E
Sell
11/30/2023Downgrade
Aurinia Pharmaceuticals Inc. (AUPH) was downgraded to E+ from D- on 11/30/2023 due to a decline in the solvency index, volatility index and valuation index. The quick ratio declined from 6 to 5.08.
Aurinia Pharmaceuticals Inc. (AUPH) was downgraded to E+ from D- on 11/30/2023 due to a decline in the solvency index, volatility index and valuation index. The quick ratio declined from 6 to 5.08.
D
Sell
3/14/2023Downgrade
Aurinia Pharmaceuticals Inc. (AUPH) was downgraded to D- from D on 3/14/2023 due to a substantial decline in the growth index, solvency index and valuation index. EBIT declined 195.82% from -$9.5M to -$28.1M, earnings per share declined from -$0.0634 to -$0.1835, and total revenue declined 49.02% from $55.78M to $28.44M.
Aurinia Pharmaceuticals Inc. (AUPH) was downgraded to D- from D on 3/14/2023 due to a substantial decline in the growth index, solvency index and valuation index. EBIT declined 195.82% from -$9.5M to -$28.1M, earnings per share declined from -$0.0634 to -$0.1835, and total revenue declined 49.02% from $55.78M to $28.44M.
D
Sell
2/9/2023Upgraded
Aurinia Pharmaceuticals Inc. (AUPH) was upgraded to D from E+ on 02/09/2023.
Aurinia Pharmaceuticals Inc. (AUPH) was upgraded to D from E+ on 02/09/2023.
E
Sell
2/8/2023Downgrade
Aurinia Pharmaceuticals Inc. (AUPH) was downgraded to E+ from D on 2/8/2023 due to a noticeable decline in the total return index, volatility index and valuation index.
Aurinia Pharmaceuticals Inc. (AUPH) was downgraded to E+ from D on 2/8/2023 due to a noticeable decline in the total return index, volatility index and valuation index.
D
Sell
5/16/2022Upgraded
Aurinia Pharmaceuticals Inc. (AUPH) was upgraded to D from D- on 05/16/2022.
Aurinia Pharmaceuticals Inc. (AUPH) was upgraded to D from D- on 05/16/2022.
D
Sell
5/1/2022Downgrade
Aurinia Pharmaceuticals Inc. (AUPH) was downgraded to D- from D+ on 5/1/2022 due to a decline in the total return index and volatility index.
Aurinia Pharmaceuticals Inc. (AUPH) was downgraded to D- from D+ on 5/1/2022 due to a decline in the total return index and volatility index.
D
Sell
4/21/2022Upgraded
Aurinia Pharmaceuticals Inc. (AUPH) was upgraded to D+ from D- on 4/21/2022 due to an increase in the valuation index.
Aurinia Pharmaceuticals Inc. (AUPH) was upgraded to D+ from D- on 4/21/2022 due to an increase in the valuation index.
D
Sell
4/20/2022Downgrade
Aurinia Pharmaceuticals Inc. (AUPH) was downgraded to D- from D+ on 4/20/2022 due to a decline in the total return index and volatility index.
Aurinia Pharmaceuticals Inc. (AUPH) was downgraded to D- from D+ on 4/20/2022 due to a decline in the total return index and volatility index.
D
Sell
3/4/2022Upgraded
Aurinia Pharmaceuticals Inc. (AUPH) was upgraded to D+ from D on 3/4/2022 due to an increase in the growth index, solvency index and valuation index. Total revenue increased 59.57% from $14.67M to $23.4M, the quick ratio increased from 7.89 to 11.85, and earnings per share increased from -$0.3913 to -$0.2513.
Aurinia Pharmaceuticals Inc. (AUPH) was upgraded to D+ from D on 3/4/2022 due to an increase in the growth index, solvency index and valuation index. Total revenue increased 59.57% from $14.67M to $23.4M, the quick ratio increased from 7.89 to 11.85, and earnings per share increased from -$0.3913 to -$0.2513.
D
Sell
11/9/2021Upgraded
Aurinia Pharmaceuticals Inc. (AUPH) was upgraded to D from D- on 11/9/2021 due to an increase in the total return index.
Aurinia Pharmaceuticals Inc. (AUPH) was upgraded to D from D- on 11/9/2021 due to an increase in the total return index.
D
Sell
11/8/2021Downgrade
Aurinia Pharmaceuticals Inc. (AUPH) was downgraded to D- from D on 11/8/2021 due to a decline in the valuation index, volatility index and solvency index. The quick ratio declined from 16.52 to 11.02.
Aurinia Pharmaceuticals Inc. (AUPH) was downgraded to D- from D on 11/8/2021 due to a decline in the valuation index, volatility index and solvency index. The quick ratio declined from 16.52 to 11.02.
D
Sell
5/19/2021Downgrade
Aurinia Pharmaceuticals Inc. (AUPH) was downgraded to D from D+ on 5/19/2021 due to a major decline in the growth index, total return index and solvency index. Operating cash flow declined 1,771.07% from $3.2M to -$53.54M, EBIT declined 527.71% from -$8.05M to -$50.54M, and earnings per share declined from -$0.0638 to -$0.3954.
Aurinia Pharmaceuticals Inc. (AUPH) was downgraded to D from D+ on 5/19/2021 due to a major decline in the growth index, total return index and solvency index. Operating cash flow declined 1,771.07% from $3.2M to -$53.54M, EBIT declined 527.71% from -$8.05M to -$50.54M, and earnings per share declined from -$0.0638 to -$0.3954.
D
Sell
3/30/2021Upgraded
Aurinia Pharmaceuticals Inc. (AUPH) was upgraded to D+ from D on 3/30/2021 due to a significant increase in the growth index, valuation index and solvency index. Total revenue increased 172,417.24% from $29 to $50.03M, operating cash flow increased 118.02% from -$30.28M to $5.46M, and EBIT increased 78.19% from -$36.64M to -$7.99M.
Aurinia Pharmaceuticals Inc. (AUPH) was upgraded to D+ from D on 3/30/2021 due to a significant increase in the growth index, valuation index and solvency index. Total revenue increased 172,417.24% from $29 to $50.03M, operating cash flow increased 118.02% from -$30.28M to $5.46M, and EBIT increased 78.19% from -$36.64M to -$7.99M.
D
Sell
3/6/2020Upgraded
Aurinia Pharmaceuticals Inc. (AUPH) was upgraded to D from D- on 3/6/2020 due to a significant increase in the total return index, solvency index and efficiency index. The quick ratio increased from 9.99 to 27.13, and total capital increased 120.37% from $124.12M to $273.52M.
Aurinia Pharmaceuticals Inc. (AUPH) was upgraded to D from D- on 3/6/2020 due to a significant increase in the total return index, solvency index and efficiency index. The quick ratio increased from 9.99 to 27.13, and total capital increased 120.37% from $124.12M to $273.52M.
D
Sell
11/29/2019Downgrade
Aurinia Pharmaceuticals Inc. (AUPH) was downgraded to D- from D on 11/29/2019 due to a noticeable decline in the total return index, growth index and valuation index. EBIT declined 45.93% from -$16.45M to -$24.01M, and earnings per share declined from -$0.1733 to -$0.2065.
Aurinia Pharmaceuticals Inc. (AUPH) was downgraded to D- from D on 11/29/2019 due to a noticeable decline in the total return index, growth index and valuation index. EBIT declined 45.93% from -$16.45M to -$24.01M, and earnings per share declined from -$0.1733 to -$0.2065.
D
Sell
5/15/2019Upgraded
Aurinia Pharmaceuticals Inc. (AUPH) was upgraded to D from D- on 5/15/2019 due to an increase in the efficiency index, volatility index and total return index. Total capital increased 24.15% from $112.58M to $139.77M, and net income increased 14.84% from -$14.59M to -$12.43M.
Aurinia Pharmaceuticals Inc. (AUPH) was upgraded to D from D- on 5/15/2019 due to an increase in the efficiency index, volatility index and total return index. Total capital increased 24.15% from $112.58M to $139.77M, and net income increased 14.84% from -$14.59M to -$12.43M.
D
Sell
11/14/2018Downgrade
Aurinia Pharmaceuticals Inc. (AUPH) was downgraded to D- from D on 11/14/2018 due to a noticeable decline in the solvency index, valuation index and total return index. The quick ratio declined from 29.65 to 20.29.
Aurinia Pharmaceuticals Inc. (AUPH) was downgraded to D- from D on 11/14/2018 due to a noticeable decline in the solvency index, valuation index and total return index. The quick ratio declined from 29.65 to 20.29.
D
Sell
3/16/2018Upgraded
Aurinia Pharmaceuticals Inc. (AUPH) was upgraded to D from D- on 3/16/2018 due to a major increase in the growth index, solvency index and total return index. Earnings per share increased from -$0.1569 to -$0.0396, EBIT increased 11.97% from -$13.79M to -$12.14M, and total revenue increased 6.9% from $29 to $31.
Aurinia Pharmaceuticals Inc. (AUPH) was upgraded to D from D- on 3/16/2018 due to a major increase in the growth index, solvency index and total return index. Earnings per share increased from -$0.1569 to -$0.0396, EBIT increased 11.97% from -$13.79M to -$12.14M, and total revenue increased 6.9% from $29 to $31.
D
Sell
1/11/2018Downgrade
Aurinia Pharmaceuticals Inc. (AUPH) was downgraded to D- from D on 1/11/2018 due to a significant decline in the total return index, volatility index and efficiency index. Net income declined 446.89% from -$2.4M to -$13.12M, and total capital declined 6.06% from $178.47M to $167.64M.
Aurinia Pharmaceuticals Inc. (AUPH) was downgraded to D- from D on 1/11/2018 due to a significant decline in the total return index, volatility index and efficiency index. Net income declined 446.89% from -$2.4M to -$13.12M, and total capital declined 6.06% from $178.47M to $167.64M.
D
Sell
5/17/2017Upgraded
Aurinia Pharmaceuticals Inc. (AUPH) was upgraded to D from D- on 5/17/2017 due to a significant increase in the total return index, solvency index and valuation index. The quick ratio increased from 5.01 to 24.32.
Aurinia Pharmaceuticals Inc. (AUPH) was upgraded to D from D- on 5/17/2017 due to a significant increase in the total return index, solvency index and valuation index. The quick ratio increased from 5.01 to 24.32.
D
Sell
9/23/2016Downgrade
Aurinia Pharmaceuticals Inc. (AUPH) was downgraded to D- from D on 9/23/2016 due to a decline in the total return index, valuation index and volatility index.
Aurinia Pharmaceuticals Inc. (AUPH) was downgraded to D- from D on 9/23/2016 due to a decline in the total return index, valuation index and volatility index.
D
Sell
8/30/2016Upgraded
Aurinia Pharmaceuticals Inc. (AUPH) was upgraded to D from D- on 8/30/2016 due to a noticeable increase in the total return index, growth index and volatility index. Earnings per share increased from -$0.1322 to -$0.1006, EBIT increased 6.09% from -$4.85M to -$4.55M, and operating cash flow increased 3.35% from -$5.22M to -$5.05M.
Aurinia Pharmaceuticals Inc. (AUPH) was upgraded to D from D- on 8/30/2016 due to a noticeable increase in the total return index, growth index and volatility index. Earnings per share increased from -$0.1322 to -$0.1006, EBIT increased 6.09% from -$4.85M to -$4.55M, and operating cash flow increased 3.35% from -$5.22M to -$5.05M.
D
Sell
3/11/2016Downgrade
Aurinia Pharmaceuticals Inc. (AUPH) was downgraded to D- from D on 3/11/2016 due to a major decline in the total return index, volatility index and growth index. Earnings per share declined from -$0.0227 to -$0.1614, operating cash flow declined 40.6% from -$3.7M to -$5.2M, and EBIT declined 6.21% from -$6.05M to -$6.43M.
Aurinia Pharmaceuticals Inc. (AUPH) was downgraded to D- from D on 3/11/2016 due to a major decline in the total return index, volatility index and growth index. Earnings per share declined from -$0.0227 to -$0.1614, operating cash flow declined 40.6% from -$3.7M to -$5.2M, and EBIT declined 6.21% from -$6.05M to -$6.43M.
D
Sell
11/16/2015Downgrade
Aurinia Pharmaceuticals Inc. (AUPH) was downgraded to D from D+ on 11/16/2015 due to a noticeable decline in the volatility index.
Aurinia Pharmaceuticals Inc. (AUPH) was downgraded to D from D+ on 11/16/2015 due to a noticeable decline in the volatility index.
D
Sell
10/30/2015Upgraded
Aurinia Pharmaceuticals Inc. (AUPH) was upgraded to D+ from D on 10/30/2015 due to a noticeable increase in the volatility index.
Aurinia Pharmaceuticals Inc. (AUPH) was upgraded to D+ from D on 10/30/2015 due to a noticeable increase in the volatility index.
D
Sell
10/15/2015Downgrade
Aurinia Pharmaceuticals Inc. (AUPH) was downgraded to D from D+ on 10/15/2015 due to a major decline in the volatility index.
Aurinia Pharmaceuticals Inc. (AUPH) was downgraded to D from D+ on 10/15/2015 due to a major decline in the volatility index.
D
Sell
8/14/2015Upgraded
Aurinia Pharmaceuticals Inc. (AUPH) was upgraded to D+ from D on 8/14/2015 due to a noticeable increase in the growth index, efficiency index and solvency index. EBIT increased 8.54% from -$5.58M to -$6.05M, and total capital increased 1.65% from $27.56M to $28.01M.
Aurinia Pharmaceuticals Inc. (AUPH) was upgraded to D+ from D on 8/14/2015 due to a noticeable increase in the growth index, efficiency index and solvency index. EBIT increased 8.54% from -$5.58M to -$6.05M, and total capital increased 1.65% from $27.56M to $28.01M.
D
Sell
7/14/2015Downgrade
Aurinia Pharmaceuticals Inc. (AUPH) was downgraded to D from D+ on 7/14/2015 due to a large decline in the volatility index and valuation index.
Aurinia Pharmaceuticals Inc. (AUPH) was downgraded to D from D+ on 7/14/2015 due to a large decline in the volatility index and valuation index.
D
Sell
6/26/2015Upgraded
Aurinia Pharmaceuticals Inc. (AUPH) was upgraded to D+ from D on 6/26/2015 due to an increase in the valuation index.
Aurinia Pharmaceuticals Inc. (AUPH) was upgraded to D+ from D on 6/26/2015 due to an increase in the valuation index.
D
Sell
5/22/2015Downgrade
Aurinia Pharmaceuticals Inc. (AUPH) was downgraded to D from D+ on 5/22/2015 due to a decline in the efficiency index and solvency index.
Aurinia Pharmaceuticals Inc. (AUPH) was downgraded to D from D+ on 5/22/2015 due to a decline in the efficiency index and solvency index.
D
Sell
5/15/2015Downgrade
Aurinia Pharmaceuticals Inc. (AUPH) was downgraded to D+ from C- on 5/15/2015 due to a substantial decline in the efficiency index, total return index and growth index. Total capital declined 38.9% from $45.11M to $27.56M, and total revenue declined 8.82% from $68 to $62.
Aurinia Pharmaceuticals Inc. (AUPH) was downgraded to D+ from C- on 5/15/2015 due to a substantial decline in the efficiency index, total return index and growth index. Total capital declined 38.9% from $45.11M to $27.56M, and total revenue declined 8.82% from $68 to $62.
C
Hold
4/23/2015Downgrade
Aurinia Pharmaceuticals Inc. (AUPH) was downgraded to C- from C on 4/23/2015 due to a decline in the solvency index, total return index and growth index.
Aurinia Pharmaceuticals Inc. (AUPH) was downgraded to C- from C on 4/23/2015 due to a decline in the solvency index, total return index and growth index.
C
Hold
3/31/2015Upgraded
Aurinia Pharmaceuticals Inc. (AUPH) was upgraded to C from D on 3/31/2015 due to a significant increase in the efficiency index, volatility index and solvency index. Net income increased 95.2% from -$2.52M to -$4.92M.
Aurinia Pharmaceuticals Inc. (AUPH) was upgraded to C from D on 3/31/2015 due to a significant increase in the efficiency index, volatility index and solvency index. Net income increased 95.2% from -$2.52M to -$4.92M.
D
Sell
8/20/2014Downgrade
Aurinia Pharmaceuticals Inc. (IPHAF) was downgraded to D from C- on 8/20/2014 due to a significant decline in the efficiency index, volatility index and valuation index. Net income declined 22.62% from -$5.19M to -$4.02M, and total capital declined 6.5% from $54.62M to $51.07M.
Aurinia Pharmaceuticals Inc. (IPHAF) was downgraded to D from C- on 8/20/2014 due to a significant decline in the efficiency index, volatility index and valuation index. Net income declined 22.62% from -$5.19M to -$4.02M, and total capital declined 6.5% from $54.62M to $51.07M.
C
Hold
6/2/2014Upgraded
Isotechnika Pharma Inc. (IPHAF) was upgraded to C- from D+ on 6/2/2014 due to a major increase in the solvency index, efficiency index and volatility index. The quick ratio increased from 0.32 to 9.67, total capital increased 272.83% from $14.65M to $54.62M, and debt to equity declined from 0.1 to 0.
Isotechnika Pharma Inc. (IPHAF) was upgraded to C- from D+ on 6/2/2014 due to a major increase in the solvency index, efficiency index and volatility index. The quick ratio increased from 0.32 to 9.67, total capital increased 272.83% from $14.65M to $54.62M, and debt to equity declined from 0.1 to 0.
D
Sell
4/4/2014Upgraded
Isotechnika Pharma Inc. (IPHAF) was upgraded to D+ from D on 4/4/2014 due to a significant increase in the volatility index, total return index and efficiency index. Total capital increased 4.95% from $13.96M to $14.65M.
Isotechnika Pharma Inc. (IPHAF) was upgraded to D+ from D on 4/4/2014 due to a significant increase in the volatility index, total return index and efficiency index. Total capital increased 4.95% from $13.96M to $14.65M.
NASDAQ
04/08/2025 4:00PM Eastern
Quotes delayed
